GuidelineHepatology (Baltimore, Md.)2018
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
17 registry-linked trialsOpen access · bronzeAbstract readPractice Guideline
In one paragraph
Guideline in Hepatology (Baltimore, Md.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 17 registered trials, which are not on this map. Cited by 2,079 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2,079citing papers in PubMed, 8 pooled it
270.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
NCT03753074 phase4active not recruitingnot on this mapstarted 2019, after this paper: background citation
A Multinational, Multicenter, Open-label, Randomized Controlled Trial to Investigate the Effectiveness of Tenofovir Alafenamide in Reducing Clinical Events in Chronic Hepatitis B Patients Beyond Treatment Indications by Current Guidelines
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial
Maintaining Antiviral Efficacy After Switching to Generic Entecavir, Baracle® in Patients Taking Baraclude® 1 mg for Antiviral Resistant Chronic Hepatitis B; A Noninferiority Study Assessing Non-detection Rate of Hepatitis B Virus DNA
Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B: A Randomized, Double-Blind, Placebo-Controlled Trial
Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy
A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection
Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.(REACH)
The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate
Prognostic Relevance of Fatty Liver Disease for Patients With Chronic Hepatitis B
NCT05410496 phase4active not recruitingnot on this mapstarted 2021, after this paper: background citation
A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection
A Prospective Cohort Study of Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B Patients Who Are Unsatisfied to Entecavir Therapy
Clinical Outcomes of HBeAg-negative Chronic Hepatitis B Patients With Indeterminate Phase: a Multi-center, Prospective, Observational Cohort Study (PILOT)
To Evaluate the Efficacy and Safety of Tenofovir Amibufenamide in Chronic Hepatitis B (CHB) Patients With Low-level Viraemia (LLV) After Entecavir Treatment
A Real-world Study of Optimizing Nucleotide-analogues-based Treatment for Chronic Hepatitis B
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
A Non-invasive Model to Predict Antiviral Therapy in Patients With Gray Zone of Chronic Hepatitis B: a Multi-center, Retrospective Study
Who cites it
2,079 citing papers in PubMed, 8 syntheses or guidelines pooled it, 4,171 citations in OpenAlex.
- Pooled it
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma.ESMO open · 2026Guideline
- Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil in chronic hepatitis b: a systematic review and meta-analysis of randomized controlled trials.BMC infectious diseases · 2026Pooled it
- Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Best practice guidelines for viral hepatitis service delivery in prisons.The Lancet. Infectious diseases · 2026Pooled it
- Hepatocellular carcinoma risk reduction associated with antiviral treatment in patients with noncirrhotic chronic hepatitis B: a systematic literature review and comparative meta-analysis.BMC gastroenterology · 2026Pooled it
- Prevalence of hepatitis B in Latin America and the Caribbean: a systematic review and meta-analysis.Archives of virology · 2026Pooled it
- A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection.CPT: pharmacometrics & systems pharmacology · 2026Pooled it
- B/F/TAF in people with both HIV-1 and hepatitis B: outcomes from the ALLIANCE open-label extension phase.AIDS research and therapy · 2026Trial
- Pharmacokinetics and safety of a new free-base formulation of tenofovir alafenamide 25 mg in healthy volunteers: a randomized, open-label, four-period, fully replicated crossover bioequivalence study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- [Clinical study on the efficacy of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia patients with chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Trial
- Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial.Journal of viral hepatitis · 2026Trial
- Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.Cancer research communications · 2026Trial
- Efficacy and safety of entecavir, peginterferon alfa-2b and GM-CSF combination therapy: the anchor randomized controlled trial.Hepatology international · 2026Trial
- Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.Alimentary pharmacology & therapeutics · 2026Trial
- Natural products targeting hepatitis B virus X protein and HBx-associated pathways in HBV-related hepatocellular carcinoma: mechanisms and therapeutic potential.Pharmaceutical biology · 2026Review
- MELD and the Risk of Mortality Between Black and White Patients with Advanced Fibrosis.Digestive diseases and sciences · 2026Article
- Trends in hepatitis B virus seroprevalence in a large cohort of adult cancer patients from 2010 to 2023.Cancer causes & control : CCC · 2026Article
- Updated Hepatitis D Seroprevalence Among Hepatitis B Surface Antigen-Positive Persons Aged ≥6 Years in the United States, National Health and Nutrition Examination Survey, 2007‒2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Nativity as a Clinical Variable in Gastric Cancer Prevention: An Immigrant Health Perspective.Journal of immigrant and minority health · 2026Review
2,019 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byReply.2018
- Commented on by
Authors and funding
9 authors at 9 institutions in 1 country.
Norah A TerraultDivision of Gastroenterology/Hepatology, University of California San Francisco, San Francisco, CA.
Anna S F LokDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.
Brian J McMahonLiver Diseases and Hepatitis Program, Alaska NativeTribal Health Consortium, Anchorage, AK.
Kyong-Mi ChangDivision of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center & University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Jessica P HwangDepartment of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Maureen M JonasDivision of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA.
Robert S BrownDivision of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY.
Natalie H BzowejOchsner Medical Center, New Orleans, LA.
John B WongDivision of Clinical Decision Making, Tufts Medical Center, Tufts University School of Medicine, Boston, MA.
Alaska Native Tribal Health Consortium · USBoston Children's Hospital · USCornell University · USOchsner Medical Center · USThe University of Texas MD Anderson Cancer Center · USTufts University · USUniversity of California, San Francisco · USUniversity of Michigan–Ann Arbor · USUniversity of Pennsylvania · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MNCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAntiviral AgentsChildCounselingHepatitis B, ChronicHepatitis B VaccinesHumansMass ScreeningAntiviral AgentsHepatitis B Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03471624ClinicalTrials.gov
NCT03753074ClinicalTrials.gov
NCT03933384ClinicalTrials.gov
NCT04069858ClinicalTrials.gov
NCT04182321ClinicalTrials.gov
NCT04201808ClinicalTrials.gov
and 11 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.